Arkansas Marijuana News

A central Arkansas man is accused of sexually assaulting a teenage girl, according to authorities.

Cory Allen Moses, 23, of Sherwood was arrested around 9 a.m. Friday at this home on Thornhill Drive on a charge of fourth-degree sexual assault, according to a police report.

The 14-year-old girl and Moses, who were described as being in a relationship, began communicating in February, authorities said. They began having sex together in March, the girl told an officer with the Sherwood Police Department.

Moses knew of her age but “he didn’t care,” the report states.

In July, the girl told authorities that she and a friend went to Moses’ home and smoked marijuana. There, the friend watched as the victim and Moses had sex, according to police.

Records show Moses also faces drug-related charges after detectives, while serving his arrest warrant, saw drug paraphernalia and smelled marijuana in his residence.

Moses remained at the Pulaski County jail as of Monday morning in lieu of $50,000 bond, according to an online inmate roster. He has a court appearance set for Feb. 6.

Read More Here...

by Arkansas Business Staff  on Monday, Dec. 11, 2017 12:00 am   2 min read

An Arkansas bank says it’s moving forward with plans to provide accounts for the state’s forthcoming medical marijuana businesses and customers. Don’t Miss Out Real Deals, Whispers and select cover stories are available only to print subscribers.

Read More Here...

Miragen Therapeutics (NASDAQ: MGEN) and Cannabis Science (OTCMKTS:CBIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Miragen Therapeutics and Cannabis Science’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Miragen Therapeutics -720.38% -80.31% -64.59% Cannabis Science -953,196.00% N/A -380.46%

Risk & Volatility

Miragen Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Cannabis Science has a beta of -3.62, suggesting that its stock price is 462% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Miragen Therapeutics and Cannabis Science, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Miragen Therapeutics 0 0 3 0 3.00 Cannabis Science 0 0 0 0 N/A

Miragen Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 200.00%. Given Miragen Therapeutics’ higher possible upside, equities research analysts clearly believe Miragen Therapeutics is more favorable than Cannabis Science.

Insider & Institutional Ownership

22.6% of Miragen Therapeutics shares are owned by institutional investors. 44.4% of Miragen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Miragen Therapeutics and Cannabis Science’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Miragen Therapeutics $3.34 million 53.44 -$12.67 million ($8.93) -0.90

Read More Here...

Cannabis Science (OTCMKTS: CBIS) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Profitability

This table compares Cannabis Science and Miragen Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Cannabis Science -953,196.00% N/A -380.46% Miragen Therapeutics -720.38% -80.31% -64.59%

Risk and Volatility

Cannabis Science has a beta of -3.62, indicating that its stock price is 462% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cannabis Science and Miragen Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cannabis Science N/A N/A N/A N/A N/A Miragen Therapeutics $3.34 million 53.44 -$12.67 million ($8.93) -0.90

Cannabis Science has higher earnings, but lower revenue than Miragen Therapeutics.

Insider and Institutional Ownership

22.6% of Miragen Therapeutics shares are owned by institutional investors. 44.4% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Cannabis Science and Miragen Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cannabis Science 0 0 0 0 N/A Miragen Therapeutics 0 0 3 0 3.00

Miragen Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 200.00%. Given Miragen

Read More Here...

Cannabis Science (OTCMKTS: CBIS) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Volatility & Risk

Cannabis Science has a beta of -3.62, meaning that its share price is 462% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.

Insider and Institutional Ownership

22.6% of Miragen Therapeutics shares are owned by institutional investors. 44.4% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Cannabis Science and Miragen Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Cannabis Science -953,196.00% N/A -380.46% Miragen Therapeutics -720.38% -80.31% -64.59%

Analyst Recommendations

This is a summary of current ratings and target prices for Cannabis Science and Miragen Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cannabis Science 0 0 0 0 N/A Miragen Therapeutics 0 0 3 0 3.00

Miragen Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 200.00%. Given Miragen Therapeutics’ higher probable upside, analysts clearly believe Miragen Therapeutics is more favorable than Cannabis Science.

Valuation & Earnings

This table compares Cannabis Science and Miragen Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cannabis Science N/A N/A N/A N/A N/A Miragen Therapeutics $3.34 million 53.44

Read More Here...

SMU’s recruiting class shrunk by two members on Sunday morning, and it was a familiar face who flipped their commitments.

Magnolia wide receiver Michael Woods and Yoakum offensive lineman Silas Robinson both flipped their commitments from SMU to Chad Morris’ new staff at Arkansas on Sunday morning.

“Due to the recent coaching changes, today I will be decommiting from Southern Methodist University,” began Woods, who was considered one of the most exciting members of SMU’s 2017 class. “I would like to thank EVERYONE at SMU that showed me hospitality. It was truly a great experience every time I was on campus. … Wit that being said, I would like to officially announce that I will be COMMITTING TO THE UNIVERSITY OF ARKANSAS.”

Robinson similarly thanked SMU before announcing his decision.

“First I would like to thank SMU for the opportunity and I wish nothing but the best for them in the future,” he wrote. “With that being said I would like to announce that I am 100% committed to the university of Arkansas.”

Both recruits are considered three-stars by 247sports.com’s composite rankings. Woods added in his message that he will enroll early at Arkansas, which hired the former SMU head coach Morris this week.

Twitter: @AdamGrosbard

This Topic is Missing Your Voice. View Comments

Read More Here...

LITTLE ROCK, Ark. — With 2018 just a few weeks away, congressional candidates are also looking ahead toward next year’s primaries. 

This week, a second Democratic candidate announced she’s jumping into the race for Arkansas’s second congressional district — currently represented by Congressman French Hill. 

Gwen Combs is a teacher and Air Force veteran.  She’s challenging Paul Spencer who teaches at Catholic High School. 

This week, Spencer joins host Jessi Turnure to talk about his campaign and push for ethics law reform.

“I’m hoping that tighter ethical control of our elections, looking at money in politics, how that goes, where it comes from, and who gets to spend it on whom, and finance issues are the big things for me and I hope that by not taking PAC money and campaign contributions from non-human entities that that serves as an example.”

Plus, we take a deep dive into the business of medical marijuana.  This week, Little Rock hosted a trade show based around the implementation of medical marijuana in Arkansas.

Capitol View airs Sunday mornings at 8:30 a.m. on KARK-TV directly before NBC’s Meet the Press.  It is hosted by Jessi Turnure.

You can watch this week’s full episode above.

Read More Here...

Marty Schladen The Columbus Dispatch @martyschladen

A cloud is looming over Ohio and every other state with a medical marijuana system.

A little-known federal budget amendment that protects growers, processors, sellers and the professionals who work with them might expire this year at the behest of the Trump administration.

Now known as the Rohrabacher-Blumenauer amendment, the measure prohibits the U.S. Justice Department from enforcing federal law against medical marijuana in places where it’s legal, as it’s been in Ohio since last year. The state has been accepting applications and issuing licenses for prospective producers and sellers in hopes of getting medical marijuana to market within a year — although those plans hit a speed bump last week when it was learned that a man who contracted to review cultivator applications had a drug-dealing conviction on his record.

Formerly known as the Rohrabacher-Farr amendment, the protection of medical marijuana had been renewed in budgets since 2014. But in September, it hit an obstacle of its own.

The House Rules Committee blocked a floor vote to keep it in the budget. An avowed marijuana opponent, Attorney General Jeff Sessions has been pressuring Republicans to axe the measure.

“This is something that’s being watched very closely,” said Thomas Rosenberger, executive director of the National Cannabis Industry Association of Ohio, a trade group.

The entire federal budget is up in the air, with Congress last week passing a short-term funding measure to keep the government open through Dec. 22.

If Rohrabacher-Blumenauer isn’t part of a longer-term deal, there could be chaos in the medical-marijuana systems in the 29 states where it’s legal. Patients could lose medicine, the professional licenses of doctors and lawyers could be threatened and investors could see their stakes disappear.

“Investors like certainty,” said Michael Correia, national government-relations manager for the National Cannabis Industry Association.

Read More Here...

Marty Schladen The Columbus Dispatch @martyschladen

A cloud is looming over Ohio and every other state with a medical marijuana system.

A little-known federal budget amendment that protects growers, processors, sellers and the professionals who work with them might expire this year at the behest of the Trump administration.

Now known as the Rohrabacher-Blumenauer amendment, the measure prohibits the U.S. Justice Department from enforcing federal law against medical marijuana in places where it’s legal, as it’s been in Ohio since last year. The state has been accepting applications and issuing licenses for prospective producers and sellers in hopes of getting medical marijuana to market within a year — although those plans hit a speed bump last week when it was learned that a man who contracted to review cultivator applications had a drug-dealing conviction on his record.

Formerly known as the Rohrabacher-Farr amendment, the protection of medical marijuana had been renewed in budgets since 2014. But in September, it hit an obstacle of its own.

The House Rules Committee blocked a floor vote to keep it in the budget. An avowed marijuana opponent, Attorney General Jeff Sessions has been pressuring Republicans to axe the measure.

“This is something that’s being watched very closely,” said Thomas Rosenberger, executive director of the National Cannabis Industry Association of Ohio, a trade group.

The entire federal budget is up in the air, with Congress last week passing a short-term funding measure to keep the government open through Dec. 22.

If Rohrabacher-Blumenauer isn’t part of a longer-term deal, there could be chaos in the medical-marijuana systems in the 29 states where it’s legal. Patients could lose medicine, the professional licenses of doctors and lawyers could be threatened and investors could see their stakes disappear.

“Investors like certainty,” said Michael Correia, national government-relations manager for the National Cannabis Industry Association.

Read More Here...

Cannabis Science (OTCMKTS: CBIS) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Volatility and Risk

Cannabis Science has a beta of -3.62, indicating that its share price is 462% less volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

Earnings and Valuation

This table compares Cannabis Science and Miragen Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cannabis Science N/A N/A N/A N/A N/A Miragen Therapeutics $3.34 million 53.44 -$12.67 million $0.15 53.33

Cannabis Science has higher earnings, but lower revenue than Miragen Therapeutics.

Insider and Institutional Ownership

22.6% of Miragen Therapeutics shares are held by institutional investors. 44.4% of Miragen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Cannabis Science and Miragen Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets Cannabis Science -953,196.00% N/A -380.46% Miragen Therapeutics -720.38% -80.31% -64.59%

Analyst Ratings

This is a summary of current ratings and price targets for Cannabis Science and Miragen Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cannabis Science 0 0 0 0 N/A Miragen Therapeutics 0 0 3 0 3.00

Miragen Therapeutics has a consensus price target of $24.00, indicating a potential upside of 200.00%. Given Miragen Therapeutics’ higher probable upside, analysts clearly believe

Read More Here...